Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 3
2008 4
2009 2
2010 1
2011 1
2012 1
2013 2
2014 4
2015 1
2016 2
2019 2
2021 1
2022 1
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Stetka J, Usart M, Kubovcakova L, Rai S, Rao TN, Sutter J, Hao-Shen H, Dirnhofer S, Geier F, Bader MS, Passweg JR, Manolova V, Dürrenberger F, Ahmed N, Schroeder T, Ganz T, Nemeth E, Silvestri L, Nai A, Camaschella C, Skoda RC. Stetka J, et al. Among authors: hao shen h. Blood. 2023 Apr 27;141(17):2127-2140. doi: 10.1182/blood.2022017976. Blood. 2023. PMID: 36758212
JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.
Rao TN, Hansen N, Stetka J, Luque Paz D, Kalmer M, Hilfiker J, Endele M, Ahmed N, Kubovcakova L, Rybarikova M, Hao-Shen H, Geier F, Beisel C, Dirnhofer S, Schroeder T, Brümmendorf TH, Wolf D, Koschmieder S, Skoda RC. Rao TN, et al. Among authors: hao shen h. Blood. 2021 Apr 22;137(16):2139-2151. doi: 10.1182/blood.2020005563. Blood. 2021. PMID: 33667305 Free PMC article.
IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.
Rai S, Zhang Y, Grockowiak E, Kimmerlin Q, Hansen N, Stoll CB, Usart M, Luque Paz D, Hao-Shen H, Zhu Y, Roux J, Bader MS, Dirnhofer S, Farady CJ, Schroeder T, Méndez-Ferrer S, Skoda RC. Rai S, et al. Among authors: hao shen h. Blood Adv. 2024 Mar 12;8(5):1234-1249. doi: 10.1182/bloodadvances.2023011338. Blood Adv. 2024. PMID: 38207211 Free PMC article.
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC. Stivala S, et al. Among authors: hao shen h. J Clin Invest. 2019 Mar 4;129(4):1596-1611. doi: 10.1172/JCI98785. eCollection 2019 Mar 4. J Clin Invest. 2019. PMID: 30730307 Free PMC article.
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC. Rao TN, et al. Among authors: hao shen h. Blood. 2019 Nov 21;134(21):1832-1846. doi: 10.1182/blood.2019000162. Blood. 2019. PMID: 31511238 Free PMC article.
Loss of Dnmt3a increased self-renewal and resistance to pegIFNα in JAK2-V617F-positive myeloproliferative neoplasms.
Usart M, Stetka J, Luque Paz D, Hansen N, Kimmerlin Q, Almeida Fonseca T, Lock M, Kubovcakova L, Karjalainen R, Hao-Shen H, Börsch A, El Taher A, Schulz J, Leroux JC, Dirnhofer S, Skoda RC. Usart M, et al. Among authors: hao shen h. Blood. 2024 Mar 17:blood.2023020270. doi: 10.1182/blood.2023020270. Online ahead of print. Blood. 2024. PMID: 38493481 Free article.
26 results